Celebrex Generics: Will Any Qualify For 180-Day Market Exclusivity?
This article was originally published in The Pink Sheet Daily
Executive Summary
Last patent covering Pfizer’s pain drug is a reissue of an earlier patent on which 180-day exclusivity has already been triggered; FDA has previously declined to award exclusivity to such patents.